general transcription factor IIIA pseudogene 6Genealiases: []
Q-omics provides the consensus-scored GTF3AP6 profile across patient tissues and cancer cell-line models. GTF3AP6 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GTF3AP6 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, GTF3AP6 RNA expression shows 5,552 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, COAD, and STAD as cancer lineages where GTF3AP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF3AP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF3AP6 survival associations across molecular data types. GTF3AP6 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF3AP6 RNA expression–survival associations across cancer types. High GTF3AP6 expression shows unfavorable associations in KICH, TGCT, KIRC, ESCA and CESC, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GTF3AP6 RNA expression.
This table summarizes GTF3AP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GTF3AP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF3AP6 shows higher tumor expression in COAD, BRCA, HNSC and LUAD. The COAD box plot shows higher GTF3AP6 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p = .011).
This table shows molecular features associated with GTF3AP6 in patient tissues and cancer cell lines. In patient samples, GTF3AP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
